Menu
Recruiting NCT06609603

Clinical Study to Evaluate the Body Fat Reducing Effects of Heat-Treated Green Tea Extract Complex

No phase Interventional Body Fat

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: HTGT compound, Placebo.
Who it may be relevant to
Registry conditions: Body Fat. Basic parameters: 19 years — 64 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized, Double-blind, Placebo-controlled, Parallel-design Clinical Study to Evaluate the Body Fat Reducing Effect of Heat-Treated Green Tea Extract Complex

Overview

This clinical study was designed to evaluate the efficacy and safety of body fat reduction in obese adults by treatment of heat-treated green tea extract complex

Detailed description

This study is a 12-week, randomized, double-blind, placebo-controlled clinical trial. 100 subjects were ranromly assigned to heat-treated green tea extract(HTGT) group and placebo group. The changes in the efficacy endpoint were evaluated after treatment of 2 capsules of HTGT once daiy for 12 weeks.

Interventions

  • Dietary supplement HTGT compound
    oral administration of HTGT compound once daily
  • Dietary supplement Placebo
    Oral administration of placebo once daily

Primary outcome measures

  • Change of body fat by DEXA [Time frame: Baseline, Week 12]
Secondary outcome measures (4)
  • Changes of total abdominal fat area, visceral fat area and subcutaneous fat area [Time frame: Baseline, Week 12]
  • Changes of indicator of lipid metabolism [Time frame: Baseline, Week 12]
  • Changes of waist circumference [Time frame: Baseline, Week 12]
  • Changes of blood biomarker [Time frame: Baseline, Week 12]

Eligibility criteria

  • lt;Inclusion Criteria\>
  • Males and females aged between 19 \~ 64 years
  • BMI 25.0 \~ 34.9 kg/m\^2
  • Waist circumferebce: 90cm or more for men, 85cm or more for women
  • Subjects who have fully understand the information provided about the study and voluntarily decided to participate
  • lt;Exclusion Criteria\>
  • Participants whose weight changed by more than 10% within the 3 months prior to visit 1
  • Individuals participated in a commercial weight loss program within 3 months prior to Visit 1
  • Participants who have undergone surgical procedures within 3 years
  • Participants who have taken obesity treatment medications within the last 3 months
  • Individuals who have taken medications affecting weight or dietary supplements for weight control within the last month
  • Subjects with uncontrolled hypertension
  • Subjects diagnosed with diabetes
  • TSH \<0.1 uIU/ml or \>10 uIU/ml
  • Creatinine \>1.5mg/dL
  • AST or ALT \> three times the upper normal limit

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

South Korea · 1 center
  • Catholic University St. Vincent Hospital — Suwon

Identifiers

NCT: NCT06609603 · AP-PV-2023-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗